Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B

Haematologica

Volumn 100, Issue 7, 2015, Pages 945-

  Kashyap, Manoj K ^a   Kumar, Deepak ^a   Villa, Reymundo ^b   La Clair, James J ^b   Benner, Chris ^e   Sasik, Roman ^d   Jones, Harrison ^a   Ghia, Emanuela M ^a   Rassenti, Laura Z ^a,c   Kipps, Thomas J ^a,c   Burkart, Michael D ^b   Castro, Januario E ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d University of California San Diego   (United States)

^e SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FD 895; MACROLIDE; PLADIENOLIDE B; PROTEIN BCL X; PROTEIN MCL 1; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; EPOXIDE; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN P53; RNA SPLICING FACTOR; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TP53 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRON RETENTION; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; SPLICEOSOME; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MUTATION; PATHOLOGY; RNA SPLICING; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; EPOXY COMPOUNDS; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MACROLIDES; MICE; MICE, INBRED BALB C; MUTATION; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA SPLICING; RNA SPLICING FACTORS; RNA, MESSENGER; SPLICEOSOMES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84936095483     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.122069     Document Type: Article

References (36)

1. Rai KR. Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy. Exp Hematol. 2007;35(4 Suppl 1):134-136.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376 (9747):1164-1174.
3. Castro JE. Treatment of patients with chronic lymphocytic leukemia with 17p deletion: the saga continues. Leuk Lymphoma. 2012;53(2):179-180.
4. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013;122(23):3723-3734.
5. Kornblihtt AR, Schor IE, Alló M, Dujardin G, Petrillo E, Muñoz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 2013;14(3):153-165.
6. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet. 2008;24(1):7-10.
7. Visconte V, Tabarroki A, Rogers HJ, et al. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. Haematologica. 2013;98(9):e105-107.
8. Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173-3186.
9. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
10. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
11. Seki-Asano M, Okazaki T, Yamagishi M, et al. Isolation and characterization of a new 12-membered macrolide FD-895. J Antibiot (Tokyo). 1994;47(12):1395-1401.
12. Asai N, Kotake Y, Niijima J, Fukuda Y, Uehara T, Sakai T. Stereochemistry of pladienolide B. J Antibiot (Tokyo). 2007;60(6): 364-369.
13. Kotake Y, Sagane K, Owa T, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol. 2007;3(9):570-575.
14. Webb TR, Joyner AS, Potter PM. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today. 2013;18(1-2):43-49.
15. Yokoi A, Kotake Y, Takahashi K, et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 2011;278(24):4870-4880.
16. Eskens FA, Ramos FJ, Burger H, et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res. 2013;19(22): 6296-6304.
17. Villa R, Kashyap MK, Kumar D, et al. Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem. 2013;56(17):6576-6582.
18. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8 (10):1640-1645.
19. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/index.html%5D.
20. Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013;5(5):47.
21. Miura K, Fujibuchi W, Unno M. Splice variants in apoptotic pathway. Exp Oncol. 2012;34(3):212-217.
22. Fox MW. The visual cliff test for the study of visual depth perception in the mouse. Anim Behav. 1965;13(2):232-233.
23. Proudfoot NJ, Furger A, Dye MJ. Integrating mRNA processing with transcription. Cell. 2002;108(4):501-512.
24. Schwaederlé M, Ghia E, Rassenti LZ, et al. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia. 2013;27(5):1214-1217.
25. Quesada V, Ramsay AJ, Lopez-Otin C. Chronic lymphocytic leukemia with SF3B1 mutation. N Engl J Med. 2012;366(26):2530.
26. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26):6904-6908.
27. Wu X, Tschumper RC, Jelinek DF. Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells. Leukemia. 2013;27(11):2264-2267.
28. Ramsay AJ, Rodríguez D, Villamor N, et al. Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia. Leukemia. 2013;27(7):1600-1603.
29. Cvitkovic I, Jurica MS. Spliceosome database: a tool for tracking components of the spliceosome. Nucleic Acids Res. 2013;41 (Database issue):D132-141.
30. Zhang Q, Li H, Jin H, Tan H, Zhang J, Sheng S. The global landscape of intron retentions in lung adenocarcinoma. BMC Med Genomics. 2014;7:15.
31. Eswaran J, Horvath A, Godbole S, et al. RNA sequencing of cancer reveals novel splicing alterations. Sci Rep. 2013;3:1689.
32. Gao Y, Koide K. Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells. ACS Chem Biol. 2013;8(5):895-900.
33. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
34. Te Raa GD, Malcikova J, Pospisilova S, et al. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(8): 1849-1853.
35. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;121(3):468-475.
36. Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(6):3854-3859.